Roujun Peng

3.9k total citations
48 papers, 1.4k citations indexed

About

Roujun Peng is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Roujun Peng has authored 48 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 15 papers in Cancer Research and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Roujun Peng's work include Breast Cancer Treatment Studies (11 papers), Breast Lesions and Carcinomas (8 papers) and HER2/EGFR in Cancer Research (7 papers). Roujun Peng is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), Breast Lesions and Carcinomas (8 papers) and HER2/EGFR in Cancer Research (7 papers). Roujun Peng collaborates with scholars based in China, Sweden and Portugal. Roujun Peng's co-authors include Zhongyu Yuan, Shusen Wang, Tao Qin, Cong Xue, Rongzhen Luo, Xiaoyu Teng, Zhong-Yu Yuan, Shu-Sen Wang, Yanxia Shi and Yi‐Xin Zeng and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Roujun Peng

47 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roujun Peng China 18 781 479 388 374 273 48 1.4k
S Dirnhofer Switzerland 25 738 0.9× 194 0.4× 564 1.5× 503 1.3× 499 1.8× 64 1.8k
David J. Byrne Australia 20 627 0.8× 342 0.7× 185 0.5× 333 0.9× 233 0.9× 51 1.2k
Maria Monne Italy 17 541 0.7× 248 0.5× 135 0.3× 628 1.7× 249 0.9× 38 1.5k
Kay Friedrichs Germany 16 674 0.9× 479 1.0× 154 0.4× 521 1.4× 118 0.4× 34 1.4k
Gisele W. B. Colleoni Brazil 21 590 0.8× 165 0.3× 348 0.9× 678 1.8× 428 1.6× 85 1.5k
Thorunn Helgason United States 15 427 0.5× 342 0.7× 166 0.4× 467 1.2× 73 0.3× 31 1.1k
Paul J. van Diest Netherlands 22 549 0.7× 454 0.9× 286 0.7× 833 2.2× 90 0.3× 40 1.6k
Magdalena Martinka Canada 26 728 0.9× 310 0.6× 348 0.9× 1.2k 3.3× 444 1.6× 62 2.3k
Ramona F. Swaby United States 22 1.1k 1.4× 278 0.6× 107 0.3× 621 1.7× 217 0.8× 83 1.8k
Leah Prentice Canada 18 552 0.7× 456 1.0× 268 0.7× 909 2.4× 254 0.9× 26 2.2k

Countries citing papers authored by Roujun Peng

Since Specialization
Citations

This map shows the geographic impact of Roujun Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roujun Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roujun Peng more than expected).

Fields of papers citing papers by Roujun Peng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roujun Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roujun Peng. The network helps show where Roujun Peng may publish in the future.

Co-authorship network of co-authors of Roujun Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Roujun Peng. A scholar is included among the top collaborators of Roujun Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roujun Peng. Roujun Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Jiang, Jiaxin, et al.. (2023). New Staging System and Prognostic Model for Malignant Phyllodes Tumor Patients without Distant Metastasis: A Development and Validation Study. Journal of Clinical Medicine. 12(5). 1889–1889. 4 indexed citations
3.
Jiang, Jiaxin, et al.. (2023). Characteristics and classification of first primary cancer patients with second primary cancer: a population-based cohort study. Clinical and Experimental Medicine. 23(8). 5051–5062. 2 indexed citations
4.
Luo, Wei, Qi Quan, Jiaxin Jiang, & Roujun Peng. (2023). An immune and epithelial–mesenchymal transition-related risk model and immunotherapy strategy for grade II and III gliomas. Frontiers in Genetics. 13. 1070630–1070630. 4 indexed citations
5.
Jiang, Jiaxin, et al.. (2022). Pan-cancer analysis identifies DDX56 as a prognostic biomarker associated with immune infiltration and drug sensitivity. Frontiers in Genetics. 13. 1004467–1004467. 3 indexed citations
6.
Liu, Shousheng, Chang Jiang, Lin Yang, et al.. (2020). First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study. Scientific Reports. 10(1). 12336–12336. 8 indexed citations
7.
Xu, Miao, Weilong Zhang, Youyuan Yao, et al.. (2019). Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies. Theranostics. 9(4). 1115–1124. 56 indexed citations
8.
Qin, Tao, Qianyi Lu, Xinke Zhang, et al.. (2017). Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. Anticancer Research. 37(8). 4575–4586. 3 indexed citations
9.
Kong, Pengfei, Ruiyan Wu, Xuechao Liu, et al.. (2016). The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis. Journal of Cancer. 7(15). 2247–2257. 28 indexed citations
10.
Xue, Cong, Roujun Peng, Ye Cao, et al.. (2016). Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer. PLoS ONE. 11(2). e0148849–e0148849. 2 indexed citations
11.
Yuan, Zhong-Yu, Ting Dai, Shu-Sen Wang, et al.. (2014). Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis. OncoTargets and Therapy. 7. 1733–1733. 35 indexed citations
12.
Yuan, Zhongyu, Rongzhen Luo, Roujun Peng, Shusen Wang, & Cong Xue. (2014). High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. OncoTargets and Therapy. 7. 1475–1475. 161 indexed citations
13.
Xia, Qing, Yuchen Cai, Roujun Peng, et al.. (2013). The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. International Journal of Oncology. 44(3). 735–744. 49 indexed citations
14.
Xue, Cong, Xi Wang, Roujun Peng, et al.. (2012). Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Science. 103(9). 1679–1687. 53 indexed citations
15.
Peng, Roujun, Zhong-Yu Yuan, Yi Xia, et al.. (2011). Circulating and Tumor-Infiltrating Foxp3+ Regulatory T Cell Subset in Chinese Patients with Extranodal NK/T Cell Lymphoma. International Journal of Biological Sciences. 7(7). 1027–1036. 8 indexed citations
16.
He, Jiehua, Roujun Peng, Zhongyu Yuan, et al.. (2011). Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Medical Oncology. 29(2). 406–410. 137 indexed citations
17.
18.
He, Jiehua, Zhongyu Yuan, Shusen Wang, et al.. (2011). EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Medical Oncology. 29(2). 401–405. 74 indexed citations
19.
Peng, Roujun, et al.. (2009). Efficacy and survival of 92 cases of Ewing's sarcoma family of tumor initially treated with multidisciplinary therapy. Chinese Journal of Cancer. 28(12). 1304–1309. 5 indexed citations
20.
Peng, Roujun. (1991). [Distribution of S-100 protein-positive dendritic cells in transitional cell carcinoma of human bladder and its relation to clinical prognosis].. PubMed. 71(10). 579–80, 40. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S Dirnhofer Breakdown of academic impact, for papers by David J. Byrne Breakdown of academic impact, for papers by Maria Monne Breakdown of academic impact, for papers by Kay Friedrichs Breakdown of academic impact, for papers by Gisele W. B. Colleoni Breakdown of academic impact, for papers by Thorunn Helgason Breakdown of academic impact, for papers by Paul J. van Diest Breakdown of academic impact, for papers by Magdalena Martinka Breakdown of academic impact, for papers by Ramona F. Swaby Breakdown of academic impact, for papers by Leah Prentice
Rankless by CCL
2026